GB2441581A - Compositions and methods for the treatment of muscle wasting - Google Patents

Compositions and methods for the treatment of muscle wasting Download PDF

Info

Publication number
GB2441581A
GB2441581A GB0616790A GB0616790A GB2441581A GB 2441581 A GB2441581 A GB 2441581A GB 0616790 A GB0616790 A GB 0616790A GB 0616790 A GB0616790 A GB 0616790A GB 2441581 A GB2441581 A GB 2441581A
Authority
GB
United Kingdom
Prior art keywords
compositions
treatment
muscle wasting
methods
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0616790A
Other versions
GB0616790D0 (en
GB2441581B (en
Inventor
Roderic M K Dale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oligos Etc Inc
Original Assignee
Oligos Etc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2005100777302A external-priority patent/CN100393320C/en
Application filed by Oligos Etc Inc filed Critical Oligos Etc Inc
Priority claimed from PCT/US2006/025657 external-priority patent/WO2008005002A1/en
Publication of GB0616790D0 publication Critical patent/GB0616790D0/en
Publication of GB2441581A publication Critical patent/GB2441581A/en
Application granted granted Critical
Publication of GB2441581B publication Critical patent/GB2441581B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and/or the promotion of muscle growth.
GB0616790A 2005-06-24 2006-06-30 Compositions and methods for the treatment of muscle wasting Expired - Fee Related GB2441581B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100777302A CN100393320C (en) 2005-06-24 2005-06-24 Oligonucleotide medicine for treating myophagism
PCT/US2006/025657 WO2008005002A1 (en) 2006-06-30 2006-06-30 Compositions and methods for the treatment of muscle wasting

Publications (3)

Publication Number Publication Date
GB0616790D0 GB0616790D0 (en) 2006-10-04
GB2441581A true GB2441581A (en) 2008-03-12
GB2441581B GB2441581B (en) 2011-01-19

Family

ID=39106232

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0616790A Expired - Fee Related GB2441581B (en) 2005-06-24 2006-06-30 Compositions and methods for the treatment of muscle wasting

Country Status (1)

Country Link
GB (1) GB2441581B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Antisense oligonucleotide against the r isophorm of human ache and uses thereof
GB0126036D0 (en) * 2001-10-30 2001-12-19 Amedis Pharm Ltd Silicon compounds
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
AU2003278957A1 (en) * 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
American Journal of Physiology - Cell Physiology (2006); Vol 291, pp C538-C545, "Gene silencing of myostatin in different...", Sato et al *
Expert Opinion on Emerging Drugs (2004); Vol 9, pp 345-361, "Emerging drugs for sarcopenia:age related muscle wasting", Lynch *

Also Published As

Publication number Publication date
GB0616790D0 (en) 2006-10-04
GB2441581B (en) 2011-01-19

Similar Documents

Publication Publication Date Title
MX2023005326A (en) Oligonucleotide compositions and methods thereof.
MX2022004101A (en) Oligonucleotide compositions and methods of use thereof.
NO20081883L (en) Modulation of glucocorticoid receptor expression
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2006031901A3 (en) SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
MX2009001962A (en) Substituted acylanilides and methods of use thereof.
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2009151546A3 (en) Methods for treating spinal muscular atrophy
MX2009000385A (en) Substituted acylanilides and methods of use thereof.
WO2007035771A3 (en) Modulation of glucagon receptor expression
DK2092065T4 (en) The antisense compounds
EP2426203A3 (en) Agents useful in treating facioscapulohumeral muscular dystrophy
EP1824872A4 (en) Rnai modulation of mll-af4 and uses thereof
WO2007042554A3 (en) Methods and compositions for treating immune disorders
MX2009006310A (en) Compositions and methods to treat muscular & cardiovascular disorders.
TW200502385A (en) Modulation of forkhead box o1a expression
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
MX2009011025A (en) Compounds with anti-cancer activity.
EP1838875A4 (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
WO2007032794A3 (en) Inhibition of viral gene expression using small interfering rna
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
ATE539758T1 (en) RNAI MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: OLIGOS ETC, INC.

Free format text: FORMER APPLICANT(S): DALE, RODERIC M K

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20100729 AND 20100804

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20220630